SPRB has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
SPRB has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.
Spruce Biosciences's Sloan Ratio for the quarter that ended in Mar. 2024 was 0.00%.
Warning Sign:
When sloan ratio (-67.75)% higher than 25% or lower than -25%, earnings are more likely to be made up of accruals.
As of Mar. 2024, Spruce Biosciences has a Sloan Ratio of 0.00%, indicating the company is in the safe zone and there is no funny business with accruals.
The historical data trend for Spruce Biosciences's Sloan Ratio % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Spruce Biosciences Annual Data | |||||||||||||||
Trend | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||
Sloan Ratio % | Get a 7-Day Free Trial | -9.95 | -1.19 | 57.52 | -32.91 | -67.75 |
Spruce Biosciences Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Sloan Ratio % | Get a 7-Day Free Trial | -33.95 | -38.27 | -67.58 | -67.75 | - |
For the Biotechnology subindustry, Spruce Biosciences's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Spruce Biosciences's Sloan Ratio % distribution charts can be found below:
* The bar in red indicates where Spruce Biosciences's Sloan Ratio % falls into.
Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.
Spruce Biosciences's Sloan Ratio for the fiscal year that ended in Dec. 2023 is calculated as
Sloan Ratio | = | (Net Income (A: Dec. 2023 ) | - | Cash Flow from Operations (A: Dec. 2023 ) |
- | Cash Flow from Investing (A: Dec. 2023 )) | / | Total Assets (A: Dec. 2023 ) | |
= | (-47.919 | - | -33.275 | |
- | 55.777) | / | 103.946 | |
= | -67.75% |
Spruce Biosciences's Sloan Ratio for the quarter that ended in Mar. 2024 is calculated as
Sloan Ratio | = | (Net Income (TTM) | - | Cash Flow from Operations (TTM)) |
- | Cash Flow from Investing (TTM)) | / | Total Assets (Q: Mar. 2024 ) | |
= | (-46.753 | - | -36.443 | |
- | 45.293) | / | 87.539 | |
= | -63.52% |
Spruce Biosciences's Net Income for the trailing twelve months (TTM) ended in Mar. 2024 was -12.824 (Jun. 2023 ) + -12.354 (Sep. 2023 ) + -9.95 (Dec. 2023 ) + -11.625 (Mar. 2024 ) = $-46.75 Mil. Spruce Biosciences's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2024 was 1.993 (Jun. 2023 ) + -12.269 (Sep. 2023 ) + -11.209 (Dec. 2023 ) + -14.958 (Mar. 2024 ) = $-36.44 Mil. Spruce Biosciences's Cash Flow from Investing for the trailing twelve months (TTM) ended in Mar. 2024 was 22 (Jun. 2023 ) + 13.993 (Sep. 2023 ) + 9.3 (Dec. 2023 ) + 0 (Mar. 2024 ) = $45.29 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Spruce Biosciences (NAS:SPRB) Sloan Ratio % Explanation
A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.
According to How to Beat the Market with the Sloan Ratio:
If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.
If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.
If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.
As of Mar. 2024, Spruce Biosciences has a Sloan Ratio of 0.00%, indicating the company is in the safe zone and there is no funny business with accruals.
Thank you for viewing the detailed overview of Spruce Biosciences's Sloan Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.
Percival Barretto-ko | director | 611 GATEWAY BOULEVARD, SUITE 740, SOUTH SAN FRANCISCO CA 94080 |
Novo Holdings A/s | 10 percent owner | TUBORG HAVNEVEJ 19, HELLERUP G7 2900 |
Niall O'donnell | director | C/O RIVERVEST VENTURE PARTNERS, 101 SOUTH HANLEY RD., STE 1850, ST. LOUIS MO 63105 |
Charlton Ralph William Iii | officer: Chief Medical Officer | 2001 JUNIPERO SERRA BOULEVARD, SUITE 640, DALY CITY CA 94104 |
Javier B. Szwarcberg | director, officer: Chief Executive Officer | 2001 JUNIPERO SERRA BOULEVARD, SUITE 640, DALY CITY CA 94014 |
Kirk Ways | director | C/O 2001 JUNIPERO SERRA BOULEVARD, SUITE 540, DALY CITY CA 94014 |
Camilla V Simpson | director | 20 ELAINE AVE., MILL VALLEY CA 94941 |
Bali Muralidhar | director | C/O EXICURE, INC., 8045 LAMON AVENUE, SUITE 410, SKOKIE IL 60077 |
Jonas Hansson | director | 18 AVENUE D'OUCHY, LAUSANNE V8 CH-1006 |
Rivervest Venture Fund Iii (ohio), L.p. | 10 percent owner | 11000 CEDAR AVENUE, SUITE 100, CLEVELAND OH 44106-3502 |
Healthcap Viii, L.p. | 10 percent owner | 18 AVENUE D'OUCHY, C/O HEALTHCAP VIII GP SA, CH 1006 LAUSANNE V8 1006 |
Moghrabi Dina Chaya | director | 22 GLEDHOW GARDENS, FLAT 2, LONDON X0 SW5 0AZ |
Omega Fund Vi Gp Manager, Ltd. | 10 percent owner | 888 BOYLSTON STREET, SUITE 1111, BOSTON MA 02199 |
Samir M. Gharib | officer: Chief Financial Officer | 2655 PINE STREET, #6, SAN FRANCISCO CA 94115 |
Richard King | director, officer: Chief Executive Officer | C/O KOS PHARMACEUTICALS INC, 1001 BRICKELL AVE 25TH FL, MIAMI FL 33131 |
From GuruFocus
By Business Wire Business Wire • 03-14-2022
By Business Wire Business Wire • 05-22-2023
By Business Wire Business Wire • 03-01-2022
By Business Wire • 08-28-2023
By Business Wire Business Wire • 06-01-2022
By Business Wire • 10-18-2023
By Business Wire • 01-04-2024
By Business Wire Business Wire • 01-05-2023
By Business Wire Business Wire • 02-01-2023
By Business Wire Business Wire • 05-31-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.